Peñalver, F., Márquez, J., Durán, S., Giraldo, P., Martin, A., Montalbán, C., . . . Group, G. (2019). Response-adapted treatment with rituximab, bendamustine, mitoxantrone, and dexamethasone followed by rituximab maintenance in patients with relapsed or refractory follicular Llymphoma after first-line immunochemotherapy: Results of the RBMDGELTAMO08 phase II trial.
Citación estilo ChicagoPeñalver, Francisco-Javier, et al. Response-adapted Treatment With Rituximab, Bendamustine, Mitoxantrone, and Dexamethasone Followed By Rituximab Maintenance in Patients With Relapsed or Refractory Follicular Llymphoma After First-line Immunochemotherapy: Results of the RBMDGELTAMO08 Phase II Trial. 2019.
Cita MLAPeñalver, Francisco-Javier, et al. Response-adapted Treatment With Rituximab, Bendamustine, Mitoxantrone, and Dexamethasone Followed By Rituximab Maintenance in Patients With Relapsed or Refractory Follicular Llymphoma After First-line Immunochemotherapy: Results of the RBMDGELTAMO08 Phase II Trial. 2019.